InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Oral Proteins and Peptides Market”-, By Type of Target Disease Indication (Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, and Type II Diabetes), Type of Molecule (Protein and Peptide), Type of Biological Target (GC-C, Insulin Receptor, Oxalate and others), Type of Mechanism of Action (Receptor Stimulation, Substrate Degradation and Others), and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031.”
The Oral Proteins and Peptides Market is estimated to reach over USD 28.17 billion by 2031, exhibiting a CAGR of 20.3% during the forecast period.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2868
Proteins and peptides, as essential biological macromolecules, possess significant therapeutic potential for the treatment of a wide range of medical conditions. Over the past three decades, and particularly within the last ten years, the development of protein-based therapeutics has advanced considerably, leading to a notable expansion in the availability of these treatments in the global pharmaceutical market.
However, oral administration of these molecules remains challenging due to their complex tertiary structures and vulnerability to enzymatic degradation in the gastrointestinal tract.
To overcome these limitations, continuous innovations in peptide formulation technologies are enhancing oral bioavailability. Significant advancements include the clinical progress of therapeutic peptides such as Octreotide, leveraging Peptelligence® technology, and oral semaglutide, utilizing Eligen® technology, which underscore the growing feasibility of oral peptide delivery systems.
Recent technological developments—including nanoparticle-based encapsulation, chemical modifications to peptide structures, and the use of permeation enhancers—have proven effective in protecting peptides from gastrointestinal degradation, positioning oral peptide therapies as practical, non-invasive alternatives to injectable formulations and improving patient adherence in chronic disease management.
Furthermore, regulatory incentives, such as the U.S. Food and Drug Administration’s Fast Track and Breakthrough Therapy designations, are expediting the approval of novel oral peptide drugs, facilitating earlier market entry. Strategic collaborations among pharmaceutical companies, biotechnology firms, and academic institutions are further advancing the sector by promoting knowledge exchange and optimizing resource utilization.
Increased research and development investments across the pharmaceutical and biotechnology industries are expected to support the discovery of novel therapeutic peptides, driving continued innovation and growth within the oral protein and peptide therapeutics market.
List of Prominent Players in the Oral Proteins and Peptides Market:
- AstraZeneca
- Biocon Chiasma
- Generex Biotechnology
- Novo Nordisk A/S
- Allergan
- Oramed Pharmaceuticals
- Proxima Concepts
- Synergy Pharmaceuticals
- Tarsa Therapeutics
- Sanofi
- F. Hoffmann-La Roche Ltd
- Novo Nordisk A/S
- Abbvie Inc.
- Pfizer Inc.
- Bausch Health Companies Inc.
- Chiesi Farmaceutici S.P.A.
- Acadia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Swk Holdings
- R-Pharm Jsc
- Entera Bio Ltd.
- Proxima Concepts
- Astrazeneca Plc
- Regor Therapeutics Group
- Terns Pharmaceuticals, Inc.
- Structure Therapeutics
- Viking Therapeutics
- Protagonist Therapeutics Inc.
- Rani Therapeutics
- Carmot Therapeutics, Inc.
- Zealand Pharma
- Sciwind Biosciences Co., Ltd.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
Advancements in drug delivery technologies—including nanoparticle-based carriers, enteric coatings, and enzyme inhibitors—have significantly enhanced the stability and bioavailability of proteins and peptides, improving the viability of oral administration.
The rising global prevalence of chronic diseases such as diabetes, cancer, and endocrine disorders is driving demand for effective, non-invasive therapeutic solutions. Regulatory agencies, notably the U.S. Food and Drug Administration (FDA), have increasingly supported innovative oral protein and peptide therapies, reinforcing investor confidence and encouraging further research and development.
Emerging oral formulations, including insulin and other peptide-based therapeutics, provide patient-centric alternatives to injectable treatments, promoting improved adherence and quality of life. Additionally, the expanding global geriatric population, which is particularly susceptible to chronic conditions, is contributing to heightened demand for advanced, easy-to-administer therapies, thereby bolstering market growth.
Challenges:
Despite technological progress, developing stable and efficacious oral protein and peptide formulations remains a complex undertaking. These formulations often require sophisticated delivery systems—such as encapsulation technologies or structural modifications—which can increase development costs and extend time to market. Low bioavailability due to enzymatic degradation in the gastrointestinal tract and the acidic gastric environment continues to limit therapeutic efficacy, posing a significant barrier to widespread adoption.
Regional Trends:
North America is expected to maintain a dominant share of the global oral protein and peptide therapeutics market throughout the forecast period, supported by substantial investments in research and development and robust funding from pharmaceutical and biotechnology sectors focused on peptide-based innovations. Regulatory incentives, including the FDA’s Fast Track and Breakthrough Therapy designations, further facilitate the expedited approval of novel oral therapeutics.
In contrast, the Asia-Pacific region is projected to achieve the highest growth rate, driven by rising healthcare expenditures, an expanding patient population, and increased awareness of peptide-based therapies. Regulatory modernization in emerging markets, coupled with significant investments in biotechnology in countries such as China and India, is fostering research initiatives and accelerating the development of innovative oral peptide treatments.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2868
Recent Developments:
- In June 2023, Pfizer Inc. declared its intention to proceed with the clinical development of a single oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate for the possible treatment of people with Type 2 diabetes mellitus (T2DM) and obesity. Subject to the outcomes of the ongoing Phase 2 trial, the company will proceed with the clinical development of lotiglipron (PF-07081532) and continue to advance the clinical program for danuglipron (PF-06882961). The business is working on a once-daily modified release version of danuglipron and anticipates having preparations for the late-stage program finalized by the end of 2023.
- In August 2023, Entera Bio, presented abstracts at the annual conference of the American Society for Bone and Mineral Research (ASBMR) on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the treatment of postmenopausal women at high risk of fracture.
Segmentation of Oral Proteins and Peptides Market.
Global Oral Proteins and Peptides Market– Type of Target Disease Indication
- Acromegaly
- Celiac Disease
- Chronic Idiopathic Constipation
- Enteric Hyperoxaluria
- Inflammatory Bowel Disease
- Type II Diabetes
Global Oral Proteins and Peptides Market – Type of Molecule
- Protein
- Peptide
Global Oral Proteins and Peptides Market – Type of Biological Target
- GC-C
- Insulin Receptor
- Oxalate
- Others
Global Oral Proteins and Peptides Market – Type of Mechanism of Action
- Receptor Stimulation
- Substrate Degradation
- Others
Global Oral Proteins and Peptides Market – By Region
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
